

Figure 1A




Figure 1B





Figure 1C



CMV = Cytomegalovirus promotor
SP= Signal peptide
VH = variable heavy chain
VL = variable light chain
TM = transmembrane domain
IRES= internal ribosomal entry site

Figure 1D




Figure 2





Figure 3






Figure 3

Figure 4




Figure 4




Figure 4




Figure 5




Figure 6





Figure 7



INTERNATIONAL SEARCH REPORT

WO 2022/029051

International application No

PCT/EPCT/EP2021/071515

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K16/42 A61P35/00 A61K39/00 C07K14/725
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2018/177966 A1 (HOFFMANN LA ROCHE [CH]; HOFFMANN LA ROCHE [US]) 4 October 2018 (2018-10-04) Anti-IgG1 Fc P329G antibody having a light chain variable region, SEQ 33 having CDRs of SEQ ID NO: 4, 5, 6 and a heavy chain variable region having HCDR1 of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 3 and HCDR2 having 2 substitutions when compared to SEQ ID NO: 2. Examples and Figures; table 2 ----- -/--	1-25

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 December 2021

Date of mailing of the international search report

13/01/2022

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Rojjo Romeo, Elena

INTERNATIONAL SEARCH REPORT

WO 2022/029051

International application No

PCT/EPCT/EP2021/071515

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DAROWSKI DIANA ET AL: "P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS 31 12 2019, vol. 32, no. 5, 3 September 2019 (2019-09-03), pages 207-218, XP002804800, ISSN: 1741-0134 abstract figure 2 Discussion -----	1-25
Y	Diana Darowski ET AL: "Abstract 4229: Anti-P329G-CAR-T cells as a novel universal CAR-T cell platform Cancer Research", Cancer Research, 1 August 2020 (2020-08-01), XP055794066, Retrieved from the Internet: URL:https://cancerres.aacrjournals.org/content/80/16_Supplement/4229 [retrieved on 2021-04-09] abstract -----	1-25
Y,P	Diana Darowski: "Entwicklung einer modularen adoptiven T-Zell-Plattform, basierend auf einem anti-P329G chimären Antigenrezeptor, für das Screening von Antikörpern im IgG1 Format und zur Anwendung für die adoptive T-Zell-Therapie", PhD thesis, 14 October 2020 (2020-10-14), XP055794072, Retrieved from the Internet: URL:https://edoc.ub.uni-muenchen.de/26846/1/Darowski_Diana.pdf [retrieved on 2021-04-09] Items 1.6, Ergebnisse, Diskussion figures 3, 4 -----	1-25